Before initiating radiotherapeutic clinical trials for these inhibitors in radioresistant CRCs, the testing of ATM inhibitors in relevant CRC mouse models should be performed to confirm their potential effectiveness as sensitizers of radioresistant tumor cells in vivo, similar to studies in mouse models for melanoma and glioblastoma [44,68]. The gene discussed is ATM; the disease is neoplasm.